Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 20Anorexia 11Cachexia 9Neoplasms 8Breast Neoplasms 8Endometrial Hyperplasia 7Weight Loss 3Recurrence 2Overweight 2Obesity 2Lung Neoplasms 2Head and Neck Neoplasms 2Body Weight Changes 2Body Weight 2Vomiting 1Turcot syndrome 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Prosthesis Failure 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Nutrition Disorders 1Neoplasms, Second Primary 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Menorrhagia 1

Interventions

ipatasertib 1entinostat 1Telemedicine 1Specimen Handling 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Hysterectomy 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Megestrol Acetate × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡